tiprankstipranks
Advertisement
Advertisement
Aardvark Therapeutics downgraded to Neutral from Buy at BTIG
PremiumThe FlyAardvark Therapeutics downgraded to Neutral from Buy at BTIG
5d ago
Aardvark downgraded to Underweight from Equal Weight at Morgan Stanley
Premium
The Fly
Aardvark downgraded to Underweight from Equal Weight at Morgan Stanley
5d ago
FDA Clinical Hold Halts Aardvark’s ARD-101 Late-Stage Program
Premium
Company Announcements
FDA Clinical Hold Halts Aardvark’s ARD-101 Late-Stage Program
6d ago
Options Volatility and Implied Earnings Moves This Week, April 06 – April 10, 2026
PremiumMarket NewsOptions Volatility and Implied Earnings Moves This Week, April 06 – April 10, 2026
1M ago
AARD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
AARD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
Aardvark Therapeutics price target lowered to $8 from $32 at B. Riley
Premium
The Fly
Aardvark Therapeutics price target lowered to $8 from $32 at B. Riley
2M ago
Aardvark Therapeutics reports Q4 EPS (81c), consensus (83c)
PremiumThe FlyAardvark Therapeutics reports Q4 EPS (81c), consensus (83c)
2M ago
Aardvark’s ARD-101 Prader-Willi Study Suspended: What Investors Should Watch Next
Premium
Company Announcements
Aardvark’s ARD-101 Prader-Willi Study Suspended: What Investors Should Watch Next
2M ago
Aardvark’s HERO Extension Trial Paused: What ARD-101’s Status Means for Investors
Premium
Company Announcements
Aardvark’s HERO Extension Trial Paused: What ARD-101’s Status Means for Investors
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100